+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Biliary Cholangitis Therapeutics Market 2024-2028

  • PDF Icon

    Report

  • 151 Pages
  • November 2023
  • Region: Global
  • TechNavio
  • ID: 5908899
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR of 8.75% during the forecast period. The report on the primary biliary cholangitis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by emergence of telehealth and remote monitoring, rising investments and developments in healthcare industry, and increase in product launches in primary biliary cholangitis therapeutics market.

The primary biliary cholangitis therapeutics market is segmented as below:

By Type

  • Primary drug
  • Secondary drug

By Distribution Channel

  • Drug stores and retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increasing demand for R&D due to government healthcare expenditure as one of the prime reasons driving the primary biliary cholangitis therapeutics market growth during the next few years. Also, increasing geriatric population and rise in the R and D investments in primary biliary cholangitis therapeutics by manufacturers will lead to sizable demand in the market.

The report on the primary biliary cholangitis therapeutics market covers the following areas:

  • Primary biliary cholangitis therapeutics market sizing
  • Primary biliary cholangitis therapeutics market forecast
  • Primary biliary cholangitis therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global primary biliary cholangitis therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Primary drug - Market size and forecast 2023-2028
Exhibit 34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
6.4 Secondary drug - Market size and forecast 2023-2028
Exhibit 38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Type
Exhibit 42: Market opportunity by Type ($ million)
Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Drug stores and retail pharmacies - Market size and forecast 2023-2028
Exhibit 48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 60: Market opportunity by Distribution Channel ($ million)
Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Canada - Market size and forecast 2023-2028
Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 111: Abbott Laboratories - Overview
Exhibit 112: Abbott Laboratories - Business segments
Exhibit 113: Abbott Laboratories - Key news
Exhibit 114: Abbott Laboratories - Key offerings
Exhibit 115: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 116: AbbVie Inc. - Overview
Exhibit 117: AbbVie Inc. - Product / Service
Exhibit 118: AbbVie Inc. - Key news
Exhibit 119: AbbVie Inc. - Key offerings
12.5 Alkem Laboratories Ltd.
Exhibit 120: Alkem Laboratories Ltd. - Overview
Exhibit 121: Alkem Laboratories Ltd. - Business segments
Exhibit 122: Alkem Laboratories Ltd. - Key news
Exhibit 123: Alkem Laboratories Ltd. - Key offerings
Exhibit 124: Alkem Laboratories Ltd. - Segment focus
12.6 Eli Lilly and Co.
Exhibit 125: Eli Lilly and Co. - Overview
Exhibit 126: Eli Lilly and Co. - Product / Service
Exhibit 127: Eli Lilly and Co. - Key news
Exhibit 128: Eli Lilly and Co. - Key offerings
12.7 GENFIT SA
Exhibit 129: GENFIT SA - Overview
Exhibit 130: GENFIT SA - Product / Service
Exhibit 131: GENFIT SA - Key offerings
12.8 Glenmark Pharmaceuticals Ltd.
Exhibit 132: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 133: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 134: Glenmark Pharmaceuticals Ltd. - Key offerings
12.9 ICE S.p.a.
Exhibit 135: ICE S.p.a. - Overview
Exhibit 136: ICE S.p.a. - Product / Service
Exhibit 137: ICE S.p.a. - Key offerings
12.10 Intercept Pharmaceuticals Inc.
Exhibit 138: Intercept Pharmaceuticals Inc. - Overview
Exhibit 139: Intercept Pharmaceuticals Inc. - Product / Service
Exhibit 140: Intercept Pharmaceuticals Inc. - Key offerings
12.11 Ipsen Pharma
Exhibit 141: Ipsen Pharma - Overview
Exhibit 142: Ipsen Pharma - Business segments
Exhibit 143: Ipsen Pharma - Key offerings
Exhibit 144: Ipsen Pharma - Segment focus
12.12 Leeford Healthcare Ltd.
Exhibit 145: Leeford Healthcare Ltd. - Overview
Exhibit 146: Leeford Healthcare Ltd. - Key offerings
12.13 NGM Biopharmaceuticals Inc.
Exhibit 147: NGM Biopharmaceuticals Inc. - Overview
Exhibit 148: NGM Biopharmaceuticals Inc. - Key offerings
12.14 Novartis AG
Exhibit 149: Novartis AG - Overview
Exhibit 150: Novartis AG - Business segments
Exhibit 151: Novartis AG - Key offerings
Exhibit 152: Novartis AG - Segment focus
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 153: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 154: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 155: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 156: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 157: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Viatris Inc.
Exhibit 158: Viatris Inc. - Overview
Exhibit 159: Viatris Inc. - Business segments
Exhibit 160: Viatris Inc. - Key news
Exhibit 161: Viatris Inc. - Key offerings
Exhibit 162: Viatris Inc. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 163: Zydus Lifesciences Ltd. - Overview
Exhibit 164: Zydus Lifesciences Ltd. - Business segments
Exhibit 165: Zydus Lifesciences Ltd. - Key offerings
Exhibit 166: Zydus Lifesciences Ltd. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 167: Inclusions checklist
Exhibit 168: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 169: Currency conversion rates for US$
13.4 Research methodology
Exhibit 170: Research methodology
Exhibit 171: Validation techniques employed for market sizing
Exhibit 172: Information sources
13.5 List of abbreviations
Exhibit 173: List of abbreviations
List of Exhibits
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Type - Market share 2023-2028 (%)
Exhibits31: Data Table on Type - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits45: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Distribution Channel ($ million)
Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Abbott Laboratories - Overview
Exhibits112: Abbott Laboratories - Business segments
Exhibits113: Abbott Laboratories - Key news
Exhibits114: Abbott Laboratories - Key offerings
Exhibits115: Abbott Laboratories - Segment focus
Exhibits116: AbbVie Inc. - Overview
Exhibits117: AbbVie Inc. - Product / Service
Exhibits118: AbbVie Inc. - Key news
Exhibits119: AbbVie Inc. - Key offerings
Exhibits120: Alkem Laboratories Ltd. - Overview
Exhibits121: Alkem Laboratories Ltd. - Business segments
Exhibits122: Alkem Laboratories Ltd. - Key news
Exhibits123: Alkem Laboratories Ltd. - Key offerings
Exhibits124: Alkem Laboratories Ltd. - Segment focus
Exhibits125: Eli Lilly and Co. - Overview
Exhibits126: Eli Lilly and Co. - Product / Service
Exhibits127: Eli Lilly and Co. - Key news
Exhibits128: Eli Lilly and Co. - Key offerings
Exhibits129: GENFIT SA - Overview
Exhibits130: GENFIT SA - Product / Service
Exhibits131: GENFIT SA - Key offerings
Exhibits132: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits133: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits134: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits135: ICE S.p.a. - Overview
Exhibits136: ICE S.p.a. - Product / Service
Exhibits137: ICE S.p.a. - Key offerings
Exhibits138: Intercept Pharmaceuticals Inc. - Overview
Exhibits139: Intercept Pharmaceuticals Inc. - Product / Service
Exhibits140: Intercept Pharmaceuticals Inc. - Key offerings
Exhibits141: Ipsen Pharma - Overview
Exhibits142: Ipsen Pharma - Business segments
Exhibits143: Ipsen Pharma - Key offerings
Exhibits144: Ipsen Pharma - Segment focus
Exhibits145: Leeford Healthcare Ltd. - Overview
Exhibits146: Leeford Healthcare Ltd. - Key offerings
Exhibits147: NGM Biopharmaceuticals Inc. - Overview
Exhibits148: NGM Biopharmaceuticals Inc. - Key offerings
Exhibits149: Novartis AG - Overview
Exhibits150: Novartis AG - Business segments
Exhibits151: Novartis AG - Key offerings
Exhibits152: Novartis AG - Segment focus
Exhibits153: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits154: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits155: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits156: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits157: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits158: Viatris Inc. - Overview
Exhibits159: Viatris Inc. - Business segments
Exhibits160: Viatris Inc. - Key news
Exhibits161: Viatris Inc. - Key offerings
Exhibits162: Viatris Inc. - Segment focus
Exhibits163: Zydus Lifesciences Ltd. - Overview
Exhibits164: Zydus Lifesciences Ltd. - Business segments
Exhibits165: Zydus Lifesciences Ltd. - Key offerings
Exhibits166: Zydus Lifesciences Ltd. - Segment focus
Exhibits167: Inclusions checklist
Exhibits168: Exclusions checklist
Exhibits169: Currency conversion rates for US$
Exhibits170: Research methodology
Exhibits171: Validation techniques employed for market sizing
Exhibits172: Information sources
Exhibits173: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global primary biliary cholangitis therapeutics market: Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing demand for R&D due to government healthcare expenditure.'

According to the report, one of the major drivers for this market is the emergence of telehealth and remote monitoring.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Eli Lilly and Co.
  • GENFIT SA
  • Glenmark Pharmaceuticals Ltd.
  • ICE S.p.a.
  • Intercept Pharmaceuticals Inc.
  • Ipsen Pharma
  • Leeford Healthcare Ltd.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.